XmAb5871

BIOLOGICAL3 trials

Sponsors

Xencor, Inc.

Conditions

Healthy VolunteersIgG4-RDSystemic Lupus Erythematosus

Phase 1

XmAb5871 Bioavailability Study

CompletedNCT02867098

Xencor, Inc.Healthy Volunteers

Start: 2016-07-31End: 2016-10-21Updated: 2017-12-08

Phase 2

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

CompletedNCT02725515

Xencor, Inc.Systemic Lupus Erythematosus

Start: 2016-02-16End: 2018-07-17Updated: 2019-08-20

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

CompletedNCT02725476

Xencor, Inc.IgG4-RD

Start: 2016-03-31End: 2017-12-31Updated: 2018-12-07

Related Papers

Pharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers.

2024-12-052 citations

Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.

2023-07-2434 citations